Table 4.
Study [ref.] | Treatment (setting) | Prior systemic treatments | Number of | Clinical benefita (%) |
Perey et al. [93] | Fulvestrant (third line) | Include tamoxifen and AIs | 67 | 28 |
Ingle et al. [92] | Fulvestrant (second and third line) | Prior nonsteroidal AIs, and tamoxifen in 79% of patients | 77 | 29 |
Petruzelka and Zimovjanova [94] | Fulvestrant (second to fifth line) | Include nonsteroidal AIs, adjuvant tamoxifen, and goserelin formestane | 44 | 52 |
Franco et al. [91] | Fulvestrant (mean prior endocrine therapies = 3.4) | Include nonsteroidal AIs, tamoxifen, megestrol acetate, exemestane, and chemotherapy | 42 | 19 |
Steger et al. [95] | Fulvestrant (second to fifth line) | Include nonsteroidal AIs, tamoxifen, exemestane, goserelin, and formestane | 88 | 57 |
Phase II clinical trials with fulvestrant following disease progression on prior endocrine therapy with aromatase inhibitors are summarized. aClinical benefit included patients who had a complete response, partial response, or stable disease for 24 weeks or longer. AI, aromatase inhibitor.